About LONGDOM Conferences:

Longdom organizes leading international conferences and webinars and is instrumental in bringing together experts and beginners for cooperative and effective research-oriented discussions. The goal of Longdom conferences is to bring together scientists at every level from different disciplines to understand and discuss during programmed topic sessions and informal gatherings. Longdom conferences will showcase innovative, cutting-edge research on the fundamental roles in addressing the challenges and translational research from academia to industry. All these opportunities will support the professional growth of younger scientists that will promote future collaborations and enhance participation and contribution to their exciting research work.

Stem Cells 2023

Stem Cell Treatment has evolved significantly in the past decade. In stem cell transplants, stem cells replace cells damaged by chemotherapy or disease or serve as a way for the donor's immune system to fight some types of cancer and blood-related diseases. To stay updated with the current research, Longdom Conferences welcome all the global participants to the 5th International Conference on Stem Cells, Tissue Engineering & Regenerative Medicine, which will be held in Rome, Italy carrying the theme "Current and Future Innovations in Stem Cell". The aim is to engage, empower, evolve and explore knowledge among both academicians and industry personnel. This conference will consist of keynote talks, session talks, oral presentations, poster presentations, B2B networking, etc.

Market Analysis Report Stem Cell Research:

End-user Insights

The pharmaceutical and biotechnology companies segment captured the largest revenue share of 52.7% in 2021. Some of the factors that can be attributed to the segment's share are the rising prevalence of chronic disease, an increase in clinical trials, an upsurge in strategic activities along with improvements in healthcare services. For instance, in August 2022, StemCyte, Inc. obtained approval from U.S. FDA for their Phase II clinical trial for Post-COVID Syndrome using umbilical cord blood stem cell therapy. Moreover, in April 2022, US FDA granted clearance to BioCardia’s Investigational New Drug (IND) application to initiate a Phase I/II clinical trial of BCDA-04 in adults improving from acute respiratory distress syndrome linked with COVID-19. Moreover, the increasing number of clinical trials coupled with the approval of stem cell-based therapies from regulatory bodies will further offer lucrative opportunities. For instance, there are around 5,000 listed clinical trials involved in stem cell research on ClinicalTrials.gov, with new clinical trials being offered every day in this field.